Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
November 2017
-
Media ReleaseNovartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in childrenTasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory…
-
Media ReleaseNovartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and TanzaniaObjective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000…
-
Media ReleaseNovartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapyPresentation of results from the Kisqali® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses…
-
Media ReleaseNew data reinforces clinical basis for switching to Sandoz biosimilar medicinesSandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
-
Media ReleaseNovartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participantsSubgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Small viruses could accelerate cell and gene therapy research
Novartis collaborates with Homology Medicines to adapt and refine genome editing technology.
-
Media ReleaseNovartis highlights its differentiated late stage pipeline at the R&D update and investor eventRTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a…
-
Media ReleaseNew Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failureEntresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
-
Media ReleasePunjab province in Pakistan signs agreement with Novartis Access against chronic diseasesPoor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will…
-
Key ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindnessBrolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
-
Conversations with Patient Advocates: Ron Hollander, president of INCA
Ron Hollander, president of the International Neuroendocrine Cancer Alliance, talks to us about patient advocacy.
-
Media ReleaseNovartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancerMONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal…
Pagination
- ‹ Previous page
- 1
- …
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- …
- 152
- › Next page